



Komodo Health analysis finds Medisafe's digital drug companions improve medication adherence and extends persistence.

Komodo Analysis

Komodo Health, a healthcare data and analytics firm, conducted an analysis using its Healthcare Map™ of 325 million U.S. patient journeys to examine the impact of Medisafe's digital drug companion on patient adherence and time on. Using claims data and a 1:3 matching formula, Komodo compared patients enrolled in a biologic digital companion program against a matched control group to measure these results.

Methodology

Medisafe worked with Komodo to identify test and control groups with the test group enrolled in a Medisafe biologic digital companion program and the control group carrying on without the Medisafe program. Medisafe users were required to have at least one relevant diagnosis, be active at least 90 days on the program, and be active on a biologic Rx while on the program. Additional matching criteria – including age, gender, and drug initiation date – helped to ensure identical cohorts between test and control groups to produce accurate results.

Komodo's Healthcare Map integrates disparate sources of patient, healthcare providers, and payer data to provide the industry's most precise view of the U.S. healthcare system. The Healthcare Map draws data from both providers and payers and is the only database of its kind to provide a longitudinal view of the entire patient journey for 325 million U.S. patients. This includes 'payer complete' (closed data) for 170 million patients, where Komodo captures 100% of these patients' health encounters. This data is coming directly from a network of 165+ US health insurance providers, so the Healthcare Map offers visibility into 3-6 times more patient encounters compared to legacy data aggregators.

Findings

The results of the study found Medisafe users in the test cohort had stronger adherence (measured by medication possession ratio, or MPR) on average compared to the control cohort of non-users. Results also found patients were more persistent on their medication when combined with Medisafe's platform.

Adherence


The study found that Medisafe program users demonstrated a 5.8% increase in adherence compared to patients who did not use Medisafe during the measured test period reporting a MPR of 95.3% vs the match control MPR of 89.5%. Additional study results compared new Medisafe users MPR to a match control group pre and post testing period. In this analysis, existing patients who joined the Medisafe program saw a 7% increase in adherence compared to the matched control group which showed no statistically significant increase over the same time. (Control patients' "start dates" were matched based on the test patient's delta between their drug initiation and Medisafe start.)

	Primary Analysis		Secondary Analysis		
	Number of Patients	Average MPR (Test Period)	Number of Patients	Average MPR (Pre-Period)	Average MPR (Test Period)
Medisafe Biologic Program Test Patients	224	95.3%	52	88.0%	95.0%
Biologic Program Control Patients	672	89.5%	168	88.6%	87.7%

$$MPR = \left(\frac{\text{Sum of days' supply for all fills in period}}{\text{Number of days in period}} \right) \times 100\%$$

Persistence

Results also found that Medisafe program users extended persistence by 15% across 52 weeks. Medisafe users remained on their medication therapy an extra 5 weeks compared to non-Medisafe users. These results analyzed patients across 52 weeks, with non-Medisafe users dropping off medication use at 33 weeks.



This study demonstrates Medisafe's human-centered design approach and its ability to influence patient engagement, helping to support increased adherence and extended persistence. Ultimately, the analysis from Komodo's Healthcare Map supports evidence of the impact of a digital drug companion to deliver ongoing support for patients.

About Medisafe

Medisafe is the leading evidence-based digital therapeutics company providing medication management solutions across the healthcare continuum, a \$300 billion problem in the US alone. Medisafe supports patients' journeys with AI driven technology that dynamically engages patients during the course of their treatment based on each patient's regimen, condition and specific circumstance. Medisafe fosters collaboration among patients, their loved ones and healthcare professionals, and partners with the healthcare ecosystem, from pharma companies to payers and providers, to improve outcomes. Seven million patient and caregiver users are registered on Medisafe's platform with over 4 billion successful medication doses on their iOS and Android smartphones and tablets and have contributed 350,000 user reviews that average 4.7 out of 5 stars in the App Store and Google Play stores.

Medisafe is a HIPAA and GDPR compliant solution and ISO 27001:2013 certified. For more information, please visit www.medisafe.com.